Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 50
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Int J Mol Sci ; 22(4)2021 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-33671948

RESUMO

Alveolar bone loss, the major feature of periodontitis, results from the activation of osteoclasts, which can consequently cause teeth to become loose and fall out; the development of drugs capable of suppressing excessive osteoclast differentiation and function is beneficial for periodontal disease patients. Given the difficulties associated with drug discovery, drug repurposing is an efficient approach for identifying alternative uses of commercially available compounds. Here, we examined the effects of PF-3845, a selective fatty acid amide hydrolase (FAAH) inhibitor, on receptor activator of nuclear factor kappa B ligand (RANKL)-mediated osteoclastogenesis, its function, and the therapeutic potential for the treatment of alveolar bone destruction in experimental periodontitis. PF-3845 significantly suppressed osteoclast differentiation and decreased the induction of nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) and the expression of osteoclast-specific markers. Actin ring formation and osteoclastic bone resorption were also reduced by PF-3845, and the anti-osteoclastogenic and anti-resorptive activities were mediated by the suppression of phosphorylation of rapidly accelerated fibrosarcoma (RAF), mitogen-activated protein kinase (MEK), extracellular signal-regulated kinase, (ERK) and nuclear factor κB (NF-κB) inhibitor (IκBα). Furthermore, the administration of PF-3845 decreased the number of osteoclasts and the amount of alveolar bone destruction caused by ligature placement in experimental periodontitis in vivo. The present study provides evidence that PF-3845 is able to suppress osteoclastogenesis and prevent alveolar bone loss, and may give new insights into its role as a treatment for osteoclast-related diseases.


Assuntos
Perda do Osso Alveolar/tratamento farmacológico , Amidoidrolases/antagonistas & inibidores , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , NF-kappa B/metabolismo , Osteogênese/efeitos dos fármacos , Periodontite/tratamento farmacológico , Piperidinas/farmacologia , Piperidinas/uso terapêutico , Piridinas/farmacologia , Piridinas/uso terapêutico , Animais , Reabsorção Óssea/tratamento farmacológico , Células Cultivadas , Modelos Animais de Doenças , Macrófagos/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Osteoclastos/metabolismo , Ligante RANK/metabolismo , Resultado do Tratamento
2.
Bioorg Med Chem Lett ; 30(18): 127429, 2020 09 15.
Artigo em Inglês | MEDLINE | ID: mdl-32731089

RESUMO

Suppression of differentiation and/or function of osteoclasts is considered an effective therapeutic strategy for osteolytic bone diseases such as periodontitis and osteoporosis. Evidence regarding the health benefits of oolong tea consumption is accumulating, and tea polyphenols have various pharmacological properties such as anti-cancer and anti-diabetes effects. In this study, we investigated the effect of oolonghomobisflavan B (OFB), a polyphenolic compound in oolong tea, on osteoclast differentiation. OFB suppressed receptor activator of nuclear factor-κB (RANKL)-induced formation of tartate-resistant acid phosphatase-positive multinuclear cells without cytotoxicity. OFB also significantly attenuated p38 phosphorylation, which is essential for RANKL-induced osteoclastogenesis, and inhibited the expressions of nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) and osteoclast-specific target genes, including dendritic cell-specific transmembrane protein and cathepsin K. Our findings suggest that OFB exhibits an anti-osteoclastogenic activity by inhibiting RANKL-mediated p38 activation, which is useful for the prevention and treatment of osteolytic bone diseases.


Assuntos
Diferenciação Celular/efeitos dos fármacos , Osteogênese/efeitos dos fármacos , Extratos Vegetais/química , Polifenóis/química , Chá/química , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo , Catepsina K/metabolismo , Células Dendríticas , Descoberta de Drogas , Ativação Enzimática/efeitos dos fármacos , Humanos , Proteínas de Membrana/metabolismo , NF-kappa B/metabolismo , Osteoclastos/citologia , Fosforilação , Extratos Vegetais/farmacologia , Polifenóis/farmacologia , Ligante RANK/metabolismo , Transdução de Sinais
3.
Biochem Biophys Res Commun ; 482(4): 1148-1153, 2017 Jan 22.
Artigo em Inglês | MEDLINE | ID: mdl-27919682

RESUMO

Cyclosporine A (CsA), an immunomodulatory drug, and is increasingly used to treat moderate dry eye syndrome and ocular surface inflammation. However, any inhibitory effect on differentiation of fibroblasts to myofibroblasts remains unclear. Here, we show that the inhibitory effect of CsA on transforming growth factor-beta2 (TGF-ß2)-induced myofibroblasts in primary cultured human pterygium fibroblasts. CsA significantly decreased mRNA and protein expression of myofibroblast-related markers including α-SMA, laminin, and fibronectin. These findings were supported by the results from immunofluorescence staining. Taken together, these results indicate the therapeutic potential of CsA against pterygium progression. Further studies are necessary to elucidate the precise intracellular signal mechanism responsible for CsA-induced downregulation of myofibroblast markers in pterygium fibroblasts.


Assuntos
Ciclosporina/farmacologia , Fibroblastos/metabolismo , Pterígio/tratamento farmacológico , Pterígio/metabolismo , Actinas/metabolismo , Diferenciação Celular , Células Cultivadas , Feminino , Fibronectinas/metabolismo , Humanos , Imunossupressores/farmacologia , Inflamação , Laminina/metabolismo , Masculino , Microscopia de Fluorescência , Músculo Liso/metabolismo , Miofibroblastos/metabolismo , Oligonucleotídeos/química , Pterígio/cirurgia , Transdução de Sinais , Software , Fator de Crescimento Transformador beta2/farmacologia
4.
J Cell Biochem ; 114(4): 942-54, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23129104

RESUMO

Here, we examined the role of ADAM10 during retinal cell differentiation in retinal sections and in vitro cultures of developing chick retinal cells from embryonic day 6 (ED6). Immunohistochemistry showed that ADAM10 is abundantly expressed in the inner zone of neuroblastic layer at ED5, and it becomes more highly expressed in the ganglion cell layer at ED7 and ED9. Western blotting confirmed that ADAM10 was expressed as an inactive pro-form that was processed to a shorter, active form in control cultured cells, but in cultures treated with an ADAM10 inhibitor (GI254023X) and ADAM10-specific siRNA, the level of mature ADAM10 decreased. Phase-contrast microscopy showed that long neurite extensions were present in untreated cultures 24 h after plating, whereas cultures treated with GI254023X showed significant decreases in neurite extension. Immunofluorescence staining revealed that there were far fewer differentiated ganglion cells in ADAM10 siRNA and GI254023X-treated cultures compared to controls, whereas the photoreceptor cells were unaltered. The Pax6 protein was more strongly detected in the differentiated ganglion cells of control cultures compared to ADAM10 siRNA and GI254023X-treated cultures. N-cadherin ectodomain shedding was apparent in control cultures after 24 h, when ganglion cell differentiation was observed, but ADAM10 siRNA and GI254023X treatment inhibited these processes. In contrast, N-cadherin staining was strongly detected in photoreceptor cells regardless of ADAM10 siRNA and GI254023X treatment. Taken together, these data indicate that the inhibition of ADAM10 can inhibit Pax6 expression and N-cadherin ectodomain shedding in retinal cells, possibly affecting neurite outgrowth and ganglion cell differentiation.


Assuntos
Proteínas ADAM/metabolismo , Caderinas/metabolismo , Diferenciação Celular , Dipeptídeos/farmacologia , Ácidos Hidroxâmicos/farmacologia , Células Ganglionares da Retina/metabolismo , Proteínas ADAM/antagonistas & inibidores , Proteínas ADAM/genética , Animais , Western Blotting , Caderinas/antagonistas & inibidores , Caderinas/genética , Células Cultivadas , Embrião de Galinha , Galinhas/metabolismo , Meios de Cultivo Condicionados , Proteínas do Olho/genética , Proteínas do Olho/metabolismo , Regulação da Expressão Gênica , Proteínas de Homeodomínio/genética , Proteínas de Homeodomínio/metabolismo , Microscopia de Contraste de Fase , Proteínas do Tecido Nervoso/metabolismo , Neuritos/efeitos dos fármacos , Neuritos/metabolismo , Fator de Transcrição PAX6 , Fatores de Transcrição Box Pareados/genética , Fatores de Transcrição Box Pareados/metabolismo , Cultura Primária de Células , Estrutura Terciária de Proteína , Transporte Proteico , RNA Interferente Pequeno/genética , RNA Interferente Pequeno/metabolismo , Proteínas Repressoras/genética , Proteínas Repressoras/metabolismo , Retina/embriologia , Retina/metabolismo , Células Fotorreceptoras Retinianas Cones/efeitos dos fármacos , Células Ganglionares da Retina/efeitos dos fármacos
5.
Nanomaterials (Basel) ; 13(5)2023 Feb 22.
Artigo em Inglês | MEDLINE | ID: mdl-36903686

RESUMO

Ultrasmall platinum nanoparticles (Pt-NPs) grafted with three types of hydrophilic and biocompatible polymers, i.e., poly(acrylic acid), poly(acrylic acid-co-maleic acid), and poly(methyl vinyl ether-alt-maleic acid) were synthesized using a one-pot polyol method. Their physicochemical and X-ray attenuation properties were characterized. All polymer-coated Pt-NPs had an average particle diameter (davg) of 2.0 nm. Polymers grafted onto Pt-NP surfaces exhibited excellent colloidal stability (i.e., no precipitation after synthesis for >1.5 years) and low cellular toxicity. The X-ray attenuation power of the polymer-coated Pt-NPs in aqueous media was stronger than that of the commercial iodine contrast agent Ultravist at the same atomic concentration and considerably stronger at the same number density, confirming their potential as computed tomography contrast agents.

6.
Biochem Biophys Res Commun ; 423(1): 67-72, 2012 Jun 22.
Artigo em Inglês | MEDLINE | ID: mdl-22634011

RESUMO

Here, we investigated whether staurosporine-mediated urokinase-type plasminogen activator (uPA) activation is involved in retinal ganglion cell (RGC) differentiation. Retinal cells were isolated from developing chick retinas at embryonic day 6 (E6). Relatively few control cells grown in serum-free medium started to form processes by 12 h. In contrast, staurosporine-treated cells had processes within 3h, and processes were evident at 8 h. Immunofluorescence staining showed that Tuj-1-positive cells with shorter neurites could be detected in control cultures at 18 h, whereas numerous Tuj-1 positive ganglion cells with longer neuritic extensions were seen in staurosporine-treated cultures. BrdU-positive proliferating cells were more numerous in control cultures than in staurosporine-treated cultures, and the BrdU staining was not detected in post-mitotic Tuj-1 positive ganglion cells. Western blotting of cell lysates showed that staurosporine induced high levels of the active form of uPA. The staurosporine-induced uPA signal was localized predominantly in the soma, neurites and axons of Tuj-1-positive ganglion cells. Amiloride, an inhibitor of uPA, markedly reduced staurosporine-induced Tuj-1 staining, neurite length, neurite number, and uPA staining versus controls. In developing retinas in ovo, amiloride administration remarkably reduced the staurosporine-induced uPA staining and RGC differentiation. Taken together, our in vitro and in vivo data collectively indicate that uPA plays a role in the staurosporine-mediated stimulation of RGC differentiation.


Assuntos
Diferenciação Celular/efeitos dos fármacos , Inibidores de Proteínas Quinases/farmacologia , Retina/embriologia , Células Ganglionares da Retina/citologia , Estaurosporina/farmacologia , Ativador de Plasminogênio Tipo Uroquinase/metabolismo , Animais , Ciclo Celular/efeitos dos fármacos , Embrião de Galinha , Galinhas , Retina/enzimologia , Células Ganglionares da Retina/enzimologia
7.
Bioorg Med Chem Lett ; 20(7): 2287-91, 2010 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-20188545

RESUMO

The synthesis and characterization of gold nanoparticles coated with Gd-chelate (Au@GdL), where L is a conjugate of DTPA and cysteine, is described. These particles are obtained by the replacement of citrate from the gold nanoparticle surfaces with gadolinium chelate (GdL). The average size of Au@GdL is 14 nm with a loading of GdL reaching up to 2.9x10(3) per particles, and they demonstrate very high R1 relaxivity (approximately 10(5) mM(-1) s(-1)) as well as X-ray attenuation. The R1 relaxivity per [Gd] is 17.9 mM(-1) s(-1). The present system also exhibits macrophage-specific property, as demonstrated by histological and TEM images as well as CT and MR, rendering itself as a new class of T1 multimodal CT/MR contrast agent.


Assuntos
Meios de Contraste , Cisteína , Gadolínio DTPA , Ouro , Imageamento por Ressonância Magnética/métodos , Nanopartículas , Animais , Meios de Contraste/química , Cisteína/química , Gadolínio DTPA/química , Ouro/química , Camundongos , Nanopartículas/química , Nanopartículas/ultraestrutura
8.
Behav Sci (Basel) ; 10(11)2020 Nov 17.
Artigo em Inglês | MEDLINE | ID: mdl-33213021

RESUMO

Mild cognitive impairment (MCI) is defined as an intermediate state of cognitive alteration between normal aging and dementia. In this study, we performed a functional network connectivity analysis using resting-state functional magnetic resonance imaging to investigate the association between changes in functional connectivity in the brain and the improvement in cognitive abilities after cognitive training. A computerized cognitive training program was used to improve the abilities of fifteen participants with MCI. The cognitive training program (Comcog), which consists of three weekly sessions totaling 90 min, was conducted with all participants over six weeks. The cognitive abilities before (pre-Comcog) and after (post-Comcog) the cognitive training process were measured using a neurocognitive function test. After the Comcog, the participants enhanced their visual and verbal memories, attention, and visuo-motor coordination. The functional connectivity between cingulo-opercular (CON) and default mode (DMN) showed significant improvements after Comcog training. Therefore, our study suggests that cognitive training may improve the cognitive abilities of participants. This improvement was associated with an increase in the functional connectivity between DMN and CON. The increase in functional connectivity after cognitive training was specifically associated with overall cognitive functions, including executive, memory, decision-making, and motivational functions.

9.
Korean J Ophthalmol ; 34(1): 1-10, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-32037744

RESUMO

PURPOSE: Diquafosol is a pharmaceutical drug used for dry eye treatment with a novel mechanism of action. It is a purinergic P2Y2 receptor agonist that promotes the secretion of tears and healing of corneal epithelial wounds. However, its inhibitory effect on hyperosmotic stress-induced inflammation in human corneal epithelial cells (HCECs) remains unclear. METHODS: A hyperosmotic stress model was established by transferring HCECs from isosmotic (312 mOsm/kg to hyperosmotic medium (500 mOsm/kg). HCECs were incubated with 500 mOsm/kg hyperosmotic medium for 30 minutes, and then treated with diquafosol (0.6-6 mg/mL) for 4 or 24 hours. Cells were then harvested and analyzed by western blot, immunocytochemistry, and real-time polymerase chain reaction to evaluate the expression of interleukin-6, tumor necrosis factor-alpha, and the phosphorylation status of nuclear factor-kappa B. RESULTS: Diquafosol significantly decreased the mRNA and protein expression of hyperosmotic stress-induced tumor necrosis factor-alpha and interleukin-6. These results were supported by immunofluorescence staining and quantitative real-time polymerase chain reaction analysis. Furthermore, diquafosol inhibits nuclear factor-kappa B activation by suppressing the phosphorylation and degradation of the inhibitor of кB. CONCLUSIONS: This study shows that diquafosol inhibits nuclear factor-kappa B signaling and inflammatory factors induced by hyperosmotic stress in HCECs. This suggests that using diquafosol for the improvement of dry eye syndrome could be effective in the treatment of inflammation-related corneal and conjunctival diseases.


Assuntos
Epitélio Corneano/metabolismo , Regulação da Expressão Gênica/efeitos dos fármacos , Interleucina-6/genética , Polifosfatos/farmacologia , RNA/genética , Nucleotídeos de Uracila/farmacologia , Western Blotting , Células Cultivadas , Síndromes do Olho Seco/genética , Síndromes do Olho Seco/metabolismo , Síndromes do Olho Seco/patologia , Epitélio Corneano/efeitos dos fármacos , Epitélio Corneano/patologia , Humanos , Interleucina-6/biossíntese , Soluções Oftálmicas , RNA/metabolismo , Transdução de Sinais , Lágrimas/metabolismo , Fator de Necrose Tumoral alfa/biossíntese , Fator de Necrose Tumoral alfa/efeitos dos fármacos , Fator de Necrose Tumoral alfa/genética
10.
J Cell Biochem ; 108(2): 476-88, 2009 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-19626665

RESUMO

In this study, temporal and spatial distribution of three TGF-beta isoforms and their downstream signaling pathways including pSmad2 and p38MAPK were examined during fibrotic wound repair. In normal chick corneas, TGF-beta1, -2, and -3 were weakly detected in Bowman's layer (BL). In healing corneas, TGF-beta1 was primarily deposited in the fibrin clot and the unwounded BL. TGF-beta2 was highly expressed in healing epithelial and endothelial cells, and numerous active fibroblasts/myofibroblasts. TGF-beta3 was mainly detected in the unwound region of basal epithelial cells. alpha-Smooth muscle actin (alpha-SMA) was initially appeared in the posterior region of repairing stroma at day 3, and was detected in the entire healing stroma by day 7. Notably, alpha-SMA was absent in the central region of healing stroma by day 14, and its staining pattern was similar to those of TGF-beta2 and p38MAPK. By contrast, pSmad2 was mainly detected in the fibroblasts. In normal cornea, laminin was mainly detected in both epithelial basement membrane (BM) and Descemet's membrane (DM). By contrast to reconstitution of the BM in the wound region, the DM was not repaired although endothelial layer was regenerated, indicating that high levels of TGF-beta2 were released into the posterior region of healing stroma on day 14. High levels of alpha-SMA staining, shown in cultured repair stromal cells from healing corneas on day 14 and in TGF-beta2 treated normal stromal cells, were significantly reduced by p38MAPK inhibition. Collectively, this study suggests that TGF-beta2-mediated myofibroblast transformation is mediated, at least partly, by the p38MAPK pathway in vivo.


Assuntos
Lesões da Córnea , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Fator de Crescimento Transformador beta/metabolismo , Cicatrização , Técnicas de Ablação , Actinas/metabolismo , Envelhecimento , Animais , Membrana Basal/metabolismo , Lâmina Limitante Anterior/metabolismo , Células Cultivadas , Galinhas , Córnea/patologia , Córnea/cirurgia , Lâmina Limitante Posterior/metabolismo , Fibrina/metabolismo , Fibrose , Laminina/metabolismo , Isoformas de Proteínas , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Receptor do Fator de Crescimento Transformador beta Tipo I , Receptores de Fatores de Crescimento Transformadores beta/antagonistas & inibidores , Proteína Smad2/metabolismo , Células Estromais/metabolismo , Células Estromais/patologia , Fatores de Tempo , Proteínas Quinases p38 Ativadas por Mitógeno/antagonistas & inibidores , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
11.
Cell Tissue Res ; 336(1): 79-89, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19221802

RESUMO

The role of matrix metalloproteinases (MMPs) in collagen fibrillogenesis during development has been studied in the well-characterized chicken metatarsal tendon. Collagen fibrils are initially assembled as intermediates, and the mature fibrils assemble by linear and lateral growth from these intermediates. We hypothesize that this involves the turnover of fibril-associated molecules mediated by the expression and activation of matrix metalloproteinase-2 (MMP-2). We demonstrate changes in the ratio of full-length to truncated MMP-2 during tendon development, consistent with enzyme activation. The level of full-length proMMP-2 remains relatively unchanged, although the truncated form of MMP-2 is highest prior to and during fibril growth. Membrane-type matrix metalloproteinase-3 (MT3-MMP, MMP-16) is fibroblast-associated and involved in the regulation of MMP-2 and in direct matrix turnover. The ratio of full-length proMT3-MMP/truncated (active) MT3-MMP has a pattern similar to that of full-length proMMP-2/truncated (active) MMP-2 during tendon development. Regulation of proMMP-2 activation involves complex formation with active MT3-MMP and TIMP-2. The constantly low TIMP-2 expression seen in tendon development is consistent with this role. Isolation of collagen fibrils from pre-fibril growth tendons (14 day) in the presence of activated MMP-2 is associated with premature fibril growth observed as increased fibril diameters compared with controls. These data implicate MMP-2/MT3-MMP in the initiation and progression of fibril growth, matrix assembly, and tendon development. This may involve the turnover of fibril-associated molecules involved in regulating linear and lateral growth, such as small leucine-rich proteoglycans and fibril-associated collagens. Activation of proMMP-2 dependent on MT3-MMP would allow the focal control of turnover.


Assuntos
Colágenos Fibrilares/metabolismo , Metaloproteinase 2 da Matriz/metabolismo , Metaloproteinase 2 da Matriz/fisiologia , Tendões/embriologia , Animais , Embrião de Galinha , Ativação Enzimática , Matriz Extracelular/metabolismo , Colágenos Fibrilares/fisiologia , Metaloproteinase 16 da Matriz/metabolismo , Metaloproteinase 16 da Matriz/fisiologia , Multimerização Proteica , Tendões/crescimento & desenvolvimento , Tendões/metabolismo , Distribuição Tecidual , Inibidores Teciduais de Metaloproteinases/metabolismo
12.
J Cell Physiol ; 214(2): 345-53, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17620312

RESUMO

Transforming growth factor beta (TGF-beta) is a multifunctional cytokine that regulates a number of biological responses including chemotaxis, cell cycle progression, differentiation, and apoptosis of cells. Even though temporal and spatial expression of TGF-beta3 suggests its role in chick limb development, it is not well characterized how TGF-beta3 regulates chondrogenic differentiation of limb bud mesenchymal cells. In this study, differential display polymerase chain reaction (DD-PCR) screening and reverse transcription PCR analysis revealed that the mRNA expression of the gap junction protein, connexin 43 (Cx43), was significantly decreased during the first treatment of TGF-beta3 for 24 h in cultured chick leg bud mesenchymal cells. Treatment of these cells with lindane, a general gap junction blocker, or expression of dominant negative Cx43 increased apoptotic cell death and decreased the level of integrin beta4 protein, in a manner similar to that observed when these cells were exposed to TGF-beta3. Similarly, exposure of cultured leg chondroblasts to a functional blocking antibody against integrin-beta4 induced an increase in apoptosis. Treatment of cells with TGF-beta3 decreased the membrane translocation of PKC-alpha, leading to activation of ERK. The increase in apoptotic cell death triggered by TGF-beta3 and dominant negative Cx43 was blocked by inhibition of ERK but increased by inhibition of PKC. Collectively, these data indicate that, in cultured chick leg bud mesenchyme cells, TGF-beta3 treatment downregulates Cx43 and induces apoptotic cell death via downregulation of integrin beta4, activation of ERK and suppression of PKC-alpha activation.


Assuntos
Condrogênese/efeitos dos fármacos , Conexina 43/metabolismo , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Integrina beta4/metabolismo , Mesoderma/efeitos dos fármacos , Fator de Crescimento Transformador beta3/farmacologia , Animais , Diferenciação Celular/efeitos dos fármacos , Fracionamento Celular , Células Cultivadas , Embrião de Galinha , Regulação para Baixo , Eletroporação , Extremidades/embriologia , Mesoderma/citologia , RNA Mensageiro/metabolismo , Asas de Animais/citologia
13.
Mol Cells ; 24(1): 9-15, 2007 Aug 31.
Artigo em Inglês | MEDLINE | ID: mdl-17846494

RESUMO

To investigate the effects of chitosan on the redifferentiation of dedifferentiated chondrocytes, we used chondrocytes obtained from a micromass culture system. Micromass cultures of chick wing bud mesenchymal cells yielded differentiated chondrocytes, but these dedifferentiated during serial monolayer subculture. When the dedifferentiated chondrocytes were cultured on chitosan membranes they regained the phenotype of differentiated chondrocytes. Expression of protein kinase C (PKC) increased during chondrogenesis, decreased during dedifferentiation, and increased again during redifferentiation. Treatment of the cultures with phorbol 12-myristate 13-acetate (PMA) inhibited redifferentiation and down-regulated PKC. In addition, the expression of p38 mitogen-activated protein (MAP) kinase increased during redifferentiation, and its inhibition suppressed redifferentiation. These findings establish a culture system for producing chondrocytes, point to a new role of chitosan in the redifferentiation of dedifferentiated chondrocytes, and show that PKC and p38 MAP kinase activities are required for chondrocyte redifferentiation in this model system.


Assuntos
Diferenciação Celular/fisiologia , Condrócitos/fisiologia , Proteína Quinase C-alfa/fisiologia , Proteínas Quinases p38 Ativadas por Mitógeno/fisiologia , Animais , Células Cultivadas , Embrião de Galinha , Quitosana , Regulação para Baixo , Extremidades/embriologia , Acetato de Tetradecanoilforbol/farmacologia
14.
Magn Reson Imaging ; 25(5): 652-6, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17540276

RESUMO

Recent studies have demonstrated the use of manganese ion (Mn2+)) as an in vivo neuronal tract tracer. In contrast to histological approaches, manganese tracing can be performed repeatedly on the same living animal. In this study, we describe the neuroaxonal tracing of the auditory pathway in the living guinea pig, relying on the fact that Mn2+ ion enters excitable cells through voltage-gated calcium channels and is an excellent MRI paramagnetic tract-tracing agent. Small focal injections of Mn2+ ion into the cochlea produced significant contrast enhancement along the known neuronal circuitry. This in vivo approach, allowing repeated measures, is expected to open new vistas to study auditory physiology and to provide new insights on in vivo axonal transport and neuronal activity in the central auditory system.


Assuntos
Vias Auditivas/anatomia & histologia , Meios de Contraste/farmacocinética , Aumento da Imagem/métodos , Imageamento por Ressonância Magnética/métodos , Manganês/farmacocinética , Animais , Cóclea , Meios de Contraste/administração & dosagem , Feminino , Cobaias , Processamento de Imagem Assistida por Computador , Injeções , Manganês/administração & dosagem
15.
J Med Chem ; 60(7): 2993-3001, 2017 04 13.
Artigo em Inglês | MEDLINE | ID: mdl-28301142

RESUMO

A novel manganese(II) complex based on an ethylenediaminetetraacetic acid (EDTA) coordination cage bearing a benzothiazole aniline (BTA) moiety (Mn-EDTA-BTA) was designed and synthesized for use as a liver-specific MRI contrast agent with high chelation stability. In addition to forming a hydrophilic, stable complex with Mn2+, this new Mn chelate was rapidly taken up by liver hepatocytes and excreted by the kidneys and biliary system. The kinetic inertness and R1 relaxivity of the complex were much higher than those of mangafodipir trisodium (MnDPDP), a clinically approved liver-specific MRI contrast agent. The diagnostic utility of this new Mn complex in MRI was demonstrated by high-sensitivity tumor detection in an animal model of liver cancer.


Assuntos
Compostos de Anilina/química , Benzotiazóis/química , Meios de Contraste/química , Ácido Edético/química , Neoplasias Hepáticas/diagnóstico por imagem , Fígado/diagnóstico por imagem , Imageamento por Ressonância Magnética/métodos , Manganês/química , Compostos de Anilina/farmacocinética , Animais , Benzotiazóis/farmacocinética , Linhagem Celular Tumoral , Quelantes/química , Quelantes/farmacocinética , Meios de Contraste/farmacocinética , Complexos de Coordenação/análogos & derivados , Complexos de Coordenação/farmacocinética , Hepatócitos/patologia , Humanos , Fígado/citologia , Fígado/patologia , Neoplasias Hepáticas/patologia , Masculino , Manganês/farmacocinética , Camundongos Endogâmicos BALB C , Camundongos Nus
16.
J Med Chem ; 60(12): 4861-4868, 2017 06 22.
Artigo em Inglês | MEDLINE | ID: mdl-28530407

RESUMO

We report the synthesis of a macrocyclic Gd chelate based on a 1,4,7,10-tetraazacyclododecane-1,4,7-trisacetic acid (DO3A) coordinationn cage bearing an ethoxybenzyl (EOB) moiety and discuss its use as a T1 hepatobiliary magnetic resonance imaging (MRI) contrast agent. The new macrocyclic liver agent shows high chelation stability and high r1 relaxivity compared with linear-type Gd chelates, which are the current clinically approved liver agents. Our macrocyclic, liver-specific Gd chelate was evaluated in vivo through biodistribution analysis and liver MRI, which demonstrated its high tumor detection sensitivity and suggested that the new Gd complex is a promising contrast agent for liver cancer imaging.


Assuntos
Meios de Contraste/química , Meios de Contraste/farmacocinética , Gadolínio/química , Fígado/diagnóstico por imagem , Imageamento por Ressonância Magnética/métodos , Animais , Sobrevivência Celular/efeitos dos fármacos , Quelantes/química , Quelantes/farmacocinética , Células HEK293 , Compostos Heterocíclicos com 1 Anel/química , Humanos , Cinética , Neoplasias Hepáticas Experimentais/diagnóstico por imagem , Masculino , Camundongos Endogâmicos ICR , Distribuição Tecidual , Ensaios Antitumorais Modelo de Xenoenxerto
17.
Int J Clin Exp Pathol ; 10(7): 7920-7928, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-31966642

RESUMO

This study aimed to investigate the neuroprotective properity of staurosporine (STS) and identify the neuroprotective mechanism of staurosporine in mouse retina ganglion cell after optic nerve injured. Mice (C57BL/6) were anaesthetised with a mixture of 5 mg/kg xylazine hydrochloride and 40 mg/kg tiletamine/zolazepam (Zoletil®). Optic nerves of the mice were crushed (Templeton JP et al., 2012). With micro-forceps, the bulbar conjunctiva was grasped and retracted, rotating the globe nasally. The exposed optic nerve was grasped approximately 1-3 mm from the globe with Dumont #N7 cross-action forceps for 10 s. One day after crushing, intravitreal injections of STS (500 nM) were administered using a Narishige IM-300 air pressure regulator. For analysing the change in ganglion cell number, the mice were allowed to live for 30 days, after which they were killed and the ganglion cell survival was assessed. A significant and marked loss of fluorescent spots was found after 30 days, with fewer 4',6-diamidino-2-phenylindole (DAPI)-expressing retinal ganglion cells (RGCs) remaining in the injured and phosphate buffered saline (PBS)-injected group than those in non-injured PBS-injected controls. However, RGC cell numbers dramatically increased in the STS intravitreal injection group. Moreover, degradation of nerve fibre (NF) was markedly reduced in the STS injection group compared with the injured and PBS-injected group by inducing astrocyte expression of Bcl-2. Our data suggested that injection of STS into the vitreous may have a potential therapeutic effect in retinal diseases such as glaucoma.

18.
PLoS One ; 12(1): e0169675, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28068383

RESUMO

We examined the connection between matrix metalloproteinase (MMP) expression/activity and pterygium fibroblast migration, and how these were affected by bevacizumab and/or cyclosporine A (CsA). Fibroblasts were obtained from 20 pterygia and 6 normal conjunctival specimens. Expression levels of MMP-3 and MMP-13 were examined after bevacizumab administration. Immunofluorescence staining was used to examine expression of both MMPs in fibroblasts migrating out from explanted pterygium tissues. Rates of cell migration from explant-cultured pterygia tissues and scratch-wounded confluent pterygium fibroblasts were examined in the presence of MMP-3 or MMP-13 inhibitors, as well as bevacizumab and/or CsA. A scratch wound healing migration assay was performed to determine the effects of bevacizumab and/or CsA. Protein expression of both MMPs in pterygium tissues and in cells migrating from organ-cultured pterygium tissues was greater than that observed in normal cells. Inhibition of the activities of both MMPs decreased their expression levels; these were also significantly reduced in bevacizumab-injected pterygium tissues. Bevacizumab significantly reduced the expression of both MMPs and cell migration. Pretreatment with CsA prior to bevacizumab exposure markedly inhibited cell migration and the expression of both MMPs. CsA enhanced the inhibitory effects of bevacizumab on pterygium fibroblast migration in vitro, possibly by inhibiting expression of both MMPs. These findings suggest that combined CsA and bevacizumab treatment may provide a potential therapeutic strategy for reducing the rate of pterygium recurrence.


Assuntos
Bevacizumab/farmacologia , Ciclosporina/farmacologia , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Metaloproteinase 13 da Matriz/metabolismo , Metaloproteinase 3 da Matriz/metabolismo , Pterígio/metabolismo , Movimento Celular/efeitos dos fármacos , Movimento Celular/genética , Regulação para Baixo , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Imuno-Histoquímica , Masculino , Metaloproteinase 13 da Matriz/genética , Metaloproteinase 3 da Matriz/genética
19.
Mol Cells ; 22(3): 353-9, 2006 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-17202865

RESUMO

The bone morphogenetic protein (BMP) family has been implicated in control of cartilage development. Here, we demonstrate that BMP-2 promotes chondrogenesis by activating p38 mitogen-activated protein kinase (MAPK), which in turn downregulates Wnt-7a/b-catenin signaling responsible for proteasomal degradation of Sox9. Exposure of mesenchymal cells to BMP-2 resulted in upregulation of Sox9 protein and a concomitant decrease in the level of b-catenin protein and Wnt-7a signaling. In agreement with this, the interaction of Sox9 with b-catenin was inhibited in the presence of BMP-2. Inhibition of the p38 MAPK pathway using a dominant negative mutant led to sustained Wnt-7a signaling and decreased Sox9 expression, with consequent inhibition of precartilage condensation and chondrogenic differentiation. Moreover, overexpression of b-catenin caused degradation of Sox9 via the ubiquitin/26S proteasome pathway. Our results collectively indicate that the increase in Sox9 protein resulting from downregulation of b-catenin/Wnt-7a signaling is mediated by p38 MAPK during BMP-2 induced chondrogenesis in chick wing bud mesenchymal cells.


Assuntos
Proteínas Aviárias/metabolismo , Proteínas Morfogenéticas Ósseas/metabolismo , Condrogênese , Regulação para Baixo , Proteínas Proto-Oncogênicas/metabolismo , Fator de Crescimento Transformador beta/metabolismo , Proteínas Wnt/metabolismo , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo , Animais , Proteína Morfogenética Óssea 2 , Embrião de Galinha , Proteínas de Grupo de Alta Mobilidade/metabolismo , Complexo de Endopeptidases do Proteassoma/metabolismo , Fatores de Transcrição SOX9 , Fatores de Transcrição/metabolismo , Transfecção , Ubiquitinas/metabolismo , Asas de Animais/embriologia , beta Catenina/metabolismo
20.
Cornea ; 35(2): 234-42, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26619385

RESUMO

PURPOSE: The purpose of this study was to compare the cytotoxicity and antiinflammatory effect of preserved and unpreserved 0.1% fluorometholone (FML). METHODS: Drug-induced morphological changes and cytotoxicity were examined in human corneal epithelial cells. Dry eye was induced in mice by treatment with 0.2% benzalkonium chloride (BAC) for the first 2 weeks, and then, the eyes (4 groups; Normal saline, BAC, preserved FML, and unpreserved FML) were treated thrice daily with each formulation for the next 2 weeks. Corneal tissues were embedded in paraffin and stained with hematoxylin and eosin for histopathological examination. Immunofluorescence staining was performed for tumor necrosis factor-α, interleukin-6, and human leukocyte antigen-DR. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay was performed to evaluate drug-induced cytotoxicity. RESULTS: BAC and preserved FML caused cell shrinkage and detachment from the plate in a dose-dependent manner, and cell viability decreased significantly. However, cytotoxicity was reduced on treatment with unpreserved FML. Hematoxylin-eosin staining revealed surface desquamation, irregular surface, loss of cell borders, and stromal shrinkage in the group treated with BAC. On BAC exposure, tumor necrosis factor-α, interleukin-6, and human leukocyte antigen-DR were strongly detected, and cytotoxicity was markedly increased, as evidenced by a positive result in the terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Ocular surface damage and inflammation were slightly reduced on treatment with preserved FML. In comparison, unpreserved FML did not induce morphological changes; moreover, decreased cell cytotoxicity and ocular surface inflammation were observed. CONCLUSIONS: The cytotoxicity of antiinflammatory eye drops evaluated in this study was induced by the preservative BAC. Accordingly, unpreserved FML is more effective than preserved eye drops in decreasing ocular inflammation.


Assuntos
Compostos de Benzalcônio/toxicidade , Síndromes do Olho Seco/tratamento farmacológico , Epitélio Corneano/efeitos dos fármacos , Fluormetolona/toxicidade , Glucocorticoides/toxicidade , Conservantes Farmacêuticos/toxicidade , Administração Tópica , Animais , Linhagem Celular , Sobrevivência Celular , Relação Dose-Resposta a Droga , Síndromes do Olho Seco/metabolismo , Epitélio Corneano/metabolismo , Feminino , Técnica Indireta de Fluorescência para Anticorpo , Antígenos HLA-DR/metabolismo , Marcação In Situ das Extremidades Cortadas , Interleucina-6/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Soluções Oftálmicas , Resultado do Tratamento , Fator de Necrose Tumoral alfa/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA